NeftalyApp Courses Partner Invest Corporate Charity Divisions

Neftaly Hospital

Neftaly Email: sayprobiz@gmail.com Call/WhatsApp: + 27 84 313 7407

Tag: Drug

Neftaly Email: sayprobiz@gmail.com Call/WhatsApp: + 27 84 313 7407

[Contact Neftaly] [About Neftaly][Services] [Recruit] [Agri] [Apply] [Login] [Courses] [Corporate Training] [Study] [School] [Sell Courses] [Career Guidance] [Training Material] [ListBusiness/NPO/Govt] [Shop] [Volunteer] [Internships] [Jobs] [Tenders] [Funding] [Learnerships] [Bursary] [Freelancers] [Sell] [Camps] [Events&Catering] [Research] [Laboratory] [Sponsor] [Machines] [Partner] [Advertise]  [Influencers] [Publish] [Write ] [Invest ] [Franchise] [Staff] [CharityNPO] [Donate] [Give] [Clinic/Hospital] [Competitions] [Travel] [Idea/Support] [Events] [Classified] [Groups] [Pages]

  • Neftaly Use of 3D Cell Culture Models for Drug Screening

    Neftaly Use of 3D Cell Culture Models for Drug Screening

  • https://hospital.neftaly.net/wp-admin/edit.php?s&post_status=all&post_type=post&action=-1&m=0&cat=0&paged=57&action2=-1

    https://hospital.neftaly.net/wp-admin/edit.php?s&post_status=all&post_type=post&action=-1&m=0&cat=0&paged=57&action2=-1

  • Neftaly Hospital HVAC Requirements for Genetic Drug Handling

    Neftaly Hospital HVAC Requirements for Genetic Drug Handling

    Neftaly: Hospital HVAC Requirements for Genetic Drug Handling

    The rise of genetic therapies marks a transformative shift in modern medicine—offering highly personalized treatments that target conditions at the molecular level. However, handling, storing, and administering genetic drugs requires strict environmental controls to preserve their efficacy and safety. At Neftaly, we specialize in developing and implementing advanced HVAC (Heating, Ventilation, and Air Conditioning) systems tailored to the unique requirements of genetic drug handling in hospital environments.

    Why HVAC Matters in Genetic Drug Handling

    Genetic drugs, including gene therapies, mRNA treatments, and cell-based products, are highly sensitive to temperature, humidity, airborne contaminants, and even pressure variations. Improper HVAC conditions can lead to:

    • Degradation of active ingredients
    • Contamination risks
    • Inaccurate dosing or treatment failure
    • Non-compliance with regulatory standards

    Neftaly’s HVAC Compliance Framework

    Neftaly designs HVAC systems and protocols based on internationally recognized best practices and specific operational needs. Our approach ensures the highest levels of safety, quality, and compliance.

    1. Temperature Control

    Precise temperature regulation is critical. We engineer HVAC systems that maintain:

    • Controlled ambient temperatures in genetic drug prep and handling areas
    • Temperature zoning for multiple therapy types or preparation processes
    • Integration with cold-chain equipment, including ultra-low freezers and refrigerators

    2. Humidity Management

    Excess moisture can compromise the integrity of genetic materials. Neftaly ensures:

    • Relative humidity (RH) between 30–60%, depending on drug specifications
    • Dehumidification units in sensitive zones
    • Real-time RH monitoring and alert systems

    3. Air Quality & Filtration

    Airborne contaminants are a critical risk in genetic drug handling. Our solutions include:

    • HEPA filtration (ISO Class 5–8, as needed)
    • Positive/negative pressure rooms to prevent cross-contamination
    • Laminar airflow systems for aseptic preparation environments

    4. Air Changes Per Hour (ACH)

    Neftaly designs systems to meet required ACH rates, optimizing air exchange to reduce particle buildup and maintain sterility. We align with:

    • USP <797>/<800> standards
    • cGMP cleanroom requirements (if applicable)

    5. Zoning & Isolation

    Hospitals require separation between genetic drug handling, storage, and administration. We develop:

    • HVAC zoning systems to isolate drug prep areas
    • Negative-pressure anterooms and storage zones where needed
    • Custom airflow designs to reduce contamination risks

    6. Monitoring & Control Systems

    Neftaly equips hospital HVAC setups with:

    • Centralized digital control panels
    • Remote monitoring via cloud dashboards
    • Automated alerts for deviations in temperature, humidity, or pressure

    7. Regulatory Compliance

    Our designs and protocols meet or exceed the requirements of:

    • FDA and EMA regulations for ATMPs (Advanced Therapy Medicinal Products)
    • WHO standards for pharmaceutical environments
    • USP, ISO, and ASHRAE guidelines

    Building the Future of Genetic Therapy with Smart Infrastructure

    Handling genetic drugs safely and effectively demands more than clinical expertise—it requires purpose-built infrastructure. Neftaly partners with hospitals and healthcare facilities to ensure that HVAC systems support every step of the genetic drug lifecycle, from preparation to administration.

    Precision therapies require precision environments. Contact Neftaly to future-proof your hospital’s HVAC systems for the genetic medicine era.

  • Neftaly Epidemiology of adverse drug events in elderly inpatients

    Neftaly Epidemiology of adverse drug events in elderly inpatients

  • Neftaly Use of antiepileptics and drug interactions in hospital settings

    Neftaly Use of antiepileptics and drug interactions in hospital settings

    Neftaly: Use of Antiepileptics and Drug Interactions in Hospital Settings

    1. Introduction

    Antiepileptic drugs (AEDs) are essential for managing seizure disorders in hospitalized patients. However, their use in the hospital setting presents unique challenges due to frequent polypharmacy, altered patient physiology, and the risk of significant drug–drug interactions (DDIs). Understanding these interactions is critical for optimizing therapeutic efficacy and minimizing adverse events.

    2. Prevalence of AED Use in Hospitals

    • AEDs are commonly prescribed for epilepsy, seizure prophylaxis after brain injury or surgery, and off-label indications such as neuropathic pain or mood stabilization.
    • Hospitalized patients often have complex medication regimens, increasing the risk of interactions.
    • Studies show that between 20-40% of patients receiving AEDs in hospitals experience clinically relevant DDIs.

    3. Mechanisms of Drug Interactions with AEDs

    • Pharmacokinetic interactions: Many AEDs induce or inhibit liver enzymes (especially cytochrome P450 enzymes), altering the metabolism of co-administered drugs.
      • Example: Carbamazepine and phenytoin are strong enzyme inducers, which can reduce the effectiveness of antibiotics, anticoagulants, and immunosuppressants.
      • Valproic acid is an enzyme inhibitor, increasing plasma levels of other drugs, including phenobarbital and lamotrigine.
    • Pharmacodynamic interactions: Additive or antagonistic effects can occur at the site of drug action.
      • Example: Combining AEDs with CNS depressants (e.g., benzodiazepines, opioids) may increase sedation and respiratory depression risk.

    4. Common Clinically Significant Drug Interactions

    AEDInteractionClinical Implication
    CarbamazepineReduces efficacy of oral contraceptives, warfarin, certain antiretroviralsRisk of contraceptive failure, thrombosis, treatment failure
    PhenytoinAlters metabolism of corticosteroids, anticoagulants, chemotherapeuticsReduced efficacy or toxicity risk
    Valproic acidIncreases levels of lamotrigine, phenobarbitalHeightened risk of toxicity and side effects
    LevetiracetamMinimal hepatic metabolism; low interaction riskPreferred in polypharmacy, but caution with CNS depressants
    LamotrigineMetabolized by glucuronidation; interaction with valproic acidIncreased risk of rash, Stevens-Johnson syndrome

    5. Impact of Drug Interactions on Hospital Outcomes

    • DDIs can lead to:
      • Seizure breakthrough or worsening seizure control.
      • Increased risk of adverse drug reactions (e.g., sedation, ataxia, rash).
      • Prolonged hospital stay due to complications.
      • Increased healthcare costs and patient morbidity.
    • For example, enzyme-inducing AEDs have been linked to reduced efficacy of anticoagulants, increasing stroke risk in patients with atrial fibrillation.

    6. Strategies for Safe AED Use in Hospitals

    • Medication reconciliation at admission and discharge to identify potential interactions.
    • Prefer AEDs with low interaction potential (e.g., levetiracetam, lacosamide) in patients on multiple medications.
    • Regular therapeutic drug monitoring (TDM) to adjust doses and avoid toxicity.
    • Close monitoring for signs of toxicity or seizure exacerbation.
    • Interdisciplinary collaboration involving neurologists, pharmacists, and primary teams.
    • Patient education about potential interactions and adherence.

    7. Conclusion

    In hospital settings, the use of antiepileptics requires careful consideration of drug–drug interactions to ensure safety and therapeutic success. Awareness of common interactions, vigilant monitoring, and choosing appropriate AEDs can help reduce adverse outcomes and improve patient care.